Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
- PMID: 23345984
- PMCID: PMC3548562
- DOI: 10.2147/CEOR.S38062
Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
Abstract
Background: This study aims to elicit the value of the willingness to pay (WTP) for a quality-adjusted life year (QALY) and to examine the factors associated with the WTP for a QALY (WTP/QALY) value under the Thai health care setting.
Methods: A community-based survey was conducted among 1191 randomly selected respondents. Each respondent was interviewed face-to-face to elicit his/her health state preference in each of three pairs of health conditions: (1) unilateral and bilateral blindness, (2) paraplegia and quadriplegia, and (3) mild and moderate allergies. A visual analog scale (VAS) and time trade off (TTO) were used as the eliciting methods. Subsequently, the respondents were asked about their WTP for the treatment and prevention of each pair of health conditions by using a bidding-game technique.
Results: With regards to treatment, the mean WTP for a QALY value (WTP/QALY(treatment)) estimated by the TTO method ranged from 59,000 to 285,000 baht (16.49 baht = US$1 purchasing power parity [PPP]). In contrast, the mean WTP for a QALY value in terms of prevention (WTP/QALY(prevention)) was significantly lower, ranging from 26,000 to 137,000 baht. Gender, household income, and hypothetical scenarios were also significant factors associated with the WTP/QALY values.
Conclusion: The WTP/QALY values elicited in this study were approximately 0.4 to 2 times Thailand's 2008 GDP per capita. These values were in line with previous studies conducted in several different settings. This study's findings clearly support the opinion that a single ceiling threshold should not be used for the resource allocation of all types of interventions.
Keywords: ceiling threshold; health resource allocation; time trade off; visual analog scale.
Similar articles
-
Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000. Pharmacoeconomics. 2009. PMID: 19908925
-
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123. BMJ Open. 2015. PMID: 26438135 Free PMC article.
-
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.Cost Eff Resour Alloc. 2020 Oct 23;18:47. doi: 10.1186/s12962-020-00241-9. eCollection 2020. Cost Eff Resour Alloc. 2020. PMID: 33110399 Free PMC article.
-
Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.PLoS One. 2022 Apr 14;17(4):e0266934. doi: 10.1371/journal.pone.0266934. eCollection 2022. PLoS One. 2022. PMID: 35421181 Free PMC article.
-
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.Eur J Health Econ. 2022 Mar;23(2):277-299. doi: 10.1007/s10198-021-01364-3. Epub 2021 Aug 21. Eur J Health Econ. 2022. PMID: 34417905
Cited by
-
Determination of a cost-effectiveness threshold for cancer interventions in Iran.Front Oncol. 2022 Dec 12;12:1039589. doi: 10.3389/fonc.2022.1039589. eCollection 2022. Front Oncol. 2022. PMID: 36578935 Free PMC article.
-
Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand.Clinicoecon Outcomes Res. 2022 Feb 2;14:61-73. doi: 10.2147/CEOR.S350606. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35140485 Free PMC article.
-
Cost-Effectiveness Thresholds: the Past, the Present and the Future.Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1. Pharmacoeconomics. 2018. PMID: 29427072 Review.
-
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015. PLoS One. 2015. PMID: 25855971 Free PMC article.
-
Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.Clinicoecon Outcomes Res. 2014 Oct 23;6:473-81. doi: 10.2147/CEOR.S67375. eCollection 2014. Clinicoecon Outcomes Res. 2014. PMID: 25364267 Free PMC article.
References
-
- Sloan FA. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press; 1995.
-
- WHO Commission on Macroeconomics and Health. Investing in health for economic development Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
-
- Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178. - PubMed
-
- Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332–342. - PubMed
-
- Ubel P, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources